COVID-19: One more lab identified at K R Hospital for testing samples

Bengaluru, Feb 24: Wanted gangster Ravi Poojary, who was arrested in South Africa and brought to India, was on Monday sent to police custody till March 7 by a Bengaluru court.

First Additional City Magistrate V Jagdish, while sending Pujari to police custody, said that there should be no interference in the investigations.

The court also asked the police to record video and audio of the interrogation process.

Poojary, who was wanted in over 200 cases of serious crime including murder and extortion, was brought to India by a team of senior officials and arrived at the Kempegowda International Airport here.

Pujari was extradited from Senegal on February 22 pursuant to an extradition request made by India in early 2019.

"He is physically fit. Questioning will begin from tomorrow. He is supporting our investigation and answering questions," Additional Director-General of Police Amar Kumar Pandey told reporters here earlier today.

Poojary, who parted ways with underworld don Chhota Rajan had jumped bail after he was arrested in Senegal in 2019 and had escaped to South Africa, where he was involved in drug trafficking and extortion.

According to sources in the Indian intelligence, Ravi Pujari was hiding with a false identity of Anthony Fernandes, a Burkina Faso passport holder, in a remote village in South Africa.

New Delhi, Jun 7: The Karnataka government has asked the railways to make announcements at originating stations that it was compulsory for passengers travelling to the state to register themselves on the ‘Seva Sindhu’ portal through which they can be tracked.

In a letter to Chairman Railway Board on Saturday, Chief Secretary of the state T M Vijay Bhaskar said many passengers are not aware of this mandatory rule of the southern state.

He said thousands of passengers are coming to Karnataka from New Delhi, Bihar, Maharashtra and other states through trains everyday, but most of them are not registered under the Seva Sindhu portal of the Government of Kamataka.

"If passengers are not registered under Seva Sindhu, the state will not be able to track them. Therefore, it is necessary to create awareness among the passengers regarding registration under the portal.

"Hence, it is requested to give instructions to origin railway stations to make announcements that ‘It is compulsory for all passengers travelling to Karnataka to register in Seva Sindhu portal. Otherwise they will not be allowed for home quarantine’, and also to give passengers awareness (about this) at the time of booking tickets,” Bhaskar said in his letter to the national transporter.

Seva Sindhu portal, under the control of the Karnataka government, provides various online services to the citizens of the state.

Currently, this portal is playing an important role in helping those stranded amid the COVID-19 pandemic to fill online registration forms for availing e-passes.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.